secwatch.observer — SEC 8-K summary
======================================

Issuer:     Autolus Therapeutics plc (AUTL)
CIK:        0001730463
Form:       8-K
Filed at:   2024-04-01T23:59:59+00:00
Accession:  0001730463-24-000050
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Autolus appoints Mike Bonney as Chair and Ravi Rao as director; John Johnson resigns effective April 1, 2024
--------------------------------------------------------------------------------

- John H. Johnson steps down as Chairman and Non-Executive Director; departure not due to disagreements.
- Mike Bonney appointed Chairman of the Board; over 30 years biotech experience, formerly CEO of Cubist Pharmaceuticals.
- Ravi Rao, M.D. appointed Non-Executive Director; current CMO of Sitryx and previous CMO at Oxford Biomedica.
- Board changes effective April 1, 2024; Bonney and Rao receive annual retainers and initial option awards.
- Press release notes recent FDA acceptance of BLA for obe-cel in r/r adult B-cell ALL as key company milestone.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730463/000173046324000050/0001730463-24-000050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730463/000173046324000050/autl-20240326.htm
  HTML page:      https://secwatch.observer/filing/0001730463-24-000050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer